Sutro Biopharma, Inc. (STRO) annual cash flow statement — 10-year operating, investing & financing history
Sutro Biopharma, Inc. (STRO) cash flow statement — 10-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Cash from Operations | -145.17M | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M | -67.8M | -65.02M | 12.68M | -37.07M | -13.15M |
| Operating CF Margin % | - | -172.94% | -308.72% | -72.6% | 5.24% | -132% | -158.71% | -152.15% | 33.01% | -71.65% | -22.02% |
| Operating CF Growth % | 156.09% | 7.47% | -71.61% | -3245% | 104.35% | -20.47% | -4.27% | -612.68% | 134.21% | -181.87% | - |
| Net Income | -180.64M | -191.09M | -227.46M | -106.79M | -119.2M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.7M |
| Depreciation & Amortization | 6.06M | 7.32M | 7.22M | 6.82M | 5.69M | 4.84M | 4.3M | 4.78M | 4.54M | 4.99M | 5.66M |
| Stock-Based Compensation | 6.78M | 14.01M | 24.69M | 24.91M | 26.3M | 23.24M | 11.92M | 10.31M | 2.87M | 1.39M | 968K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 7.24M | -41.01M | -1.3M | -1.5M | 3M | 80K |
| Other Non-Cash Items | 44.01M | 42.92M | -4.88M | -2.17M | -13.65M | 6.16M | 606K | 193K | -517K | 132K | 98K |
| Working Capital Changes | -21.39M | -50.4M | 8.9M | -34.38M | 104.41M | -17.62M | -11.49M | -23.26M | 42.61M | -26.9M | -21.66M |
| Change in Receivables | 2.2M | 4.64M | 27.46M | -28.96M | 5.34M | -6.89M | 739K | -3.81M | -865K | -1.05M | -171K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -4.54M | -58K | -1.25M | -1.67M | -354K | -389K |
| Change in Payables | -974K | -2.47M | 706K | 4.81M | -1.23M | 6.43M | -947K | 2.25M | 209K | -473K | 874K |
| Cash from Investing | 32.79M | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M | 604K | -51.13M | -80.19M | 32.6M | 9.59M |
| Capital Expenditures | -446K | -1.7M | -3.1M | -4.32M | -7.86M | -15.32M | -7.13M | -3.48M | -1.56M | -3.32M | -4.39M |
| CapEx % of Revenue | 0.98% | 1.65% | 4.99% | 2.81% | 11.59% | 24.76% | 16.69% | 8.15% | 4.05% | 6.41% | 7.36% |
| Acquisitions | 0 | 0 | 0 | 0 | 28.74M | 0 | 0 | 47.65M | 0 | 0 | 16K |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -28.73M | 9K | 89K | -47.65M | 80K | 80K | 16K |
| Cash from Financing | 102.69M | 44K | 94.05M | 137.55M | 48.31M | 3.26M | 269.25M | -4.18M | 170.78M | 14.64M | 177K |
| Debt Issued (Net) | 0 | 0 | -4.08M | -12.5M | -9.38M | 0 | 15M | -5M | 0 | 15M | 0 |
| Equity Issued (Net) | 103.11M | 376K | 96.53M | 11.97M | 56.27M | -994K | 251.41M | 1.11M | 169.18M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 160K | 0 | 0 | 0 | 0 | -7K | 0 | -327K | 0 | 0 | 0 |
| Other Financing | -412K | -332K | 1.61M | 138.08M | 1.42M | 4.25M | 2.83M | -297K | 1.61M | -362K | 177K |
| Net Change in Cash | -9.69M | -132.17M | 121.02M | 22.01M | 16.84M | -175.74M | 202.05M | -120.34M | 103.28M | 10.17M | -3.38M |
| Free Cash Flow | -145.62M | -178.93M | -194.64M | -115.93M | -4.31M | -97M | -74.93M | -68.5M | 11.13M | -40.39M | -17.55M |
| FCF Margin % | -318.63% | -174.59% | -313.71% | -75.41% | -6.36% | -156.76% | -175.39% | -160.3% | 28.96% | -78.06% | -29.38% |
| FCF Growth % | 42.22% | 8.07% | -67.89% | -2590.44% | 95.56% | -29.46% | -9.38% | -715.71% | 127.55% | -130.18% | - |
| FCF per Share | -8.79 | -21.06 | -25.33 | -19.27 | -0.85 | -21.03 | -23.00 | -29.84 | 4.87 | -57.72 | -397.71 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.93x | 0.84x | 1.05x | -0.03x | 0.77x | 2.11x | 1.17x | -0.36x | 1.88x | -7.73x |
| Interest Paid | 0 | 0 | 310K | 1.13M | 0 | 2.05M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 15K | 0 | 17.52M | 379K | 0 | 103K | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying STRO stock.
Sutro Biopharma, Inc. (STRO) generated $-177.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Sutro Biopharma, Inc. (STRO) reported negative free cash flow of $178.9M in 2025, indicating capital requirements exceeded cash from operations.
Sutro Biopharma, Inc. (STRO) spent $1.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.